Biosynthetic gas vesicles as a novel ultrasound contrast agent for diagnosing and treating myocardial infarction

hGVs demonstrated superior imaging performance and penetration capabilities specifically at the myocardial infarction sites in rats.Their ability to provide positive contrast and deliver oxygen via ultrasound-targeted bubble destruction enables improved diagnosis and treatment of MI.